Bajaj Healthcare has applied for a compulsory license against Eli Lilly for Baricitinib, citing affordability concerns. The post also covers the EPO’s decision on double patenting, updates from the IP5 meeting on AI patents, and new initiatives by WHO, WTO, and WIPO.
Read more about After Natco, Bajaj Healthcare files compulsory license against Eli Lilly; EPO Enlarged Board of Appeal issues decision on ‘double patenting’ and moreTag: Baricitinib
Natco withdraws compulsory license, signs agreement with Eli Lilly for Barcitinib; Patent Office notifies extension of timelines and more
Natco Pharma has withdrawn its compulsory license application for Baricitinib following an agreement with Eli Lilly. The Indian Patent Office has extended procedural deadlines, and other significant updates in IP law are discussed, including ongoing litigation and international proposals.
Read more about Natco withdraws compulsory license, signs agreement with Eli Lilly for Barcitinib; Patent Office notifies extension of timelines and moreNatco files compulsory license request; USA approves temporary patent waiver; Ericsson and Samsung settle dispute and more
Natco seeks a compulsory license for Baricitinib, while the USA backs a temporary COVID-19 vaccine patent waiver. The EU critiques the US approach, and Ericsson and Samsung resolve their ongoing patent dispute. WIPO also releases a new guide on industrial design registration.
Read more about Natco files compulsory license request; USA approves temporary patent waiver; Ericsson and Samsung settle dispute and more